Upper and lower respiratory tract infections
Cefprozil is indicated for the treatment of patients with mild to moderate infections caused by susceptible strains. Infections include:
- Lower respiratory tract infections: acute bronchitis, acute exacerbations of chronic bronchitis, community acquired pneumonia.
- Upper respiratory tract and ear infections: otitis media, sinusitis, tonsillitis and pharyngitis.
- Uncomplicated skin and soft tissue infections.
Cefprozil is a preparation of Cefprozil, which is a semi synthetic, second-generation cephalosporin antibiotic indicated for the treatment of patients with mild to moderate infections caused by susceptible strains.
- Ensures treatment success in pediatric GAS pharyngitis/tonsillitis
- A drug of choice for pediatric patients with tonsilopharyngitis
- Guarantees treatment success in SSTI
Cefprozil is a semi synthetic, second-generation cephalosporin antibiotic. Cefprozil is active in vitro against both gram positive and gram negative bacteria. The bactericidal activity of cefprozil results from the inhibition of cell wall synthesis via affinity for penicillin-binding proteins (PBPs).
Nephrotoxicity has been reported following concomitant administration of aminoglycoside antibiotics and cephalosporin antibiotics. Concomitant administration of probenecid doubled the AUC for cefprozil.
The adverse reactions to cefprozil are similar to those observed with other orally administered cephalosporins. Cefprozil was usually well tolerated in controlled clinical trials. The most common adverse effects of cefprozil are diarrhea, nausea, vomiting, abdominal pain, rash, urticaria, dizziness, hyperactivity, insomnia, confusion etc.
Pregnancy category B. There are no adequate and well-controlled studies in pregnant women. This drug should be used during pregnancy only if clearly needed. Small amounts of cefprozil (<0.3% of dose) have been detected in human milk following administration of a single 1 gram dose to lactating women. Caution should be exercised when cefprozil is administered to a nursing woman, since the effect of cefprozil on nursing infants is unknown.
In patients with known or suspected renal impairment, careful clinical observation and appropriate laboratory studies should be done prior to and during therapy. Prolonged use of cefprozil may result in the overgrowth of nonsusceptible organisms. Cefprozil should be prescribed with caution in individuals with a history of gastrointestinal disease particularly colitis.
Second generation Cephalosporins
Cefprozil powder for suspension should be stored in a cool, dry place (preferably below 30°C) and should be protected from light. Keep out of reach of children.
